Apelin and ischemia modified albumin levels in heart failure patients with sleep disordered breathing

Apelin is an adipocytokine produced in cardiomyocytes, vascular smooth muscle cells and endothelium, with an important role in the regulation of vascular tone and fluid balance. Plasma apelin levels are reduced in patients with heart failure. Ischemia modified albumin (IMA) production is stimulated by hypoxia and increases rapidly following myocardial ischemia.We aimed to assess the role of IMA and apelin in the pathogenesis of SDB related with heart failure. Consecutive 50 patients with heart failure were prospectively evaluated with full night polysomnography for the presence of SDB between April 2016 and May 2017. Cases diagnosed with SDB subsequently underwent BPAP titration. Apelin 13 and IMA levels were measured at baseline, following BPAP titration and after 3 months of BPAP therapy. SDB was detected in 48 of 50 patients (96%) with heart failure. Baseline apelin level was 8.635±6.344pg/ml and 16.353±11.999pg/ml on the morning of BPAP titration (p=0.022). IMA level was 4.511±2.026 IU/ml at baseline and 3.977±1.985 IU/ml on the morning of BPAP titration (p=0.302). Both baseline apelin and IMA levels were inversely correlated with apnea hypopnea index (r= -0.332, p=0.03) for apelin and (r= -0.399, p=0.009) for IMA. Apelin and IMA were assessed after 3 months of BPAP treatment but there was no significant difference with respect to baseline.Plasma apelin level increased after single night PAP treatment but the effect did not carry over after pro...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Sleep and control of breathing Source Type: research